$126 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VCEL | VERICEL CORP CMN | $1,293,000 | -3.5% | 362,157 | 0.0% | 1.02% | -8.8% | |
| ASMB | ASSEMBLY BIOSCIENCES INC CMN | $1,252,000 | +45.4% | 65,000 | 0.0% | 0.99% | +37.4% | |
| ESPR | ESPERION THERAPEUTICS INC CMN | $1,226,000 | -11.7% | 15,000 | 0.0% | 0.97% | -16.6% | |
| MACK | MERRIMACK PHARMACEUTICALS INC CMN | $890,000 | +4.1% | 72,009 | 0.0% | 0.70% | -1.7% | |
| CMRX | CHIMERIX, INC. CMN | $885,000 | +22.6% | 19,152 | 0.0% | 0.70% | +15.9% | |
| STML | STEMLINE THERAPEUTICS INC CMN | $883,000 | -18.6% | 75,000 | 0.0% | 0.70% | -23.1% | |
| XNPT | XENOPORT INC CMN | $797,000 | -13.9% | 130,000 | 0.0% | 0.63% | -18.7% | |
| RLYP | RELYPSA, INC. CMN | $596,000 | -8.2% | 18,000 | 0.0% | 0.47% | -13.2% | |
| ACHN | ACHILLION PHARMACEUTICALS INC CMN | $591,000 | -10.2% | 66,704 | 0.0% | 0.47% | -15.1% | |
| ARWR | ARROWHEAD RESEARCH CORP CMN | $587,000 | +5.6% | 82,133 | 0.0% | 0.46% | -0.2% | |
| ZGNX | ZOGENIX, INC. CMN | $504,000 | +22.6% | 300,000 | 0.0% | 0.40% | +16.0% | |
| RPRXZ | WTS/REPROS THERAPEUTICS INC. SERIES B 2.4500 EXP02/07/2016call | $456,000 | -23.6% | 98,000 | 0.0% | 0.36% | -27.8% | |
| ACRX | ACELRX PHARMACEUTICALS, INC. CMN | $424,000 | +9.8% | 99,959 | 0.0% | 0.34% | +3.7% | |
| KBIO | KALOBIOS PHARMACEUTICALS INC CMN | $358,000 | -2.2% | 746,467 | 0.0% | 0.28% | -7.5% | |
| NHLD | NATIONAL HOLDINGS CORP CMN | $321,000 | -8.0% | 89,530 | 0.0% | 0.25% | -13.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.